McKesson Corporation

source: coverage-next-full ticker: MCK step: "01" title: Business Overview — Segments, Model, Strategic Position created: 2026-05-29

Step 01 — Business Overview

Company Description

McKesson Corporation is the largest pharmaceutical distributor in the United States and one of the largest companies in the world by revenue (~$309B in FY2024). Founded in 1833 as a drug wholesaler in New York, McKesson has evolved into a diversified healthcare infrastructure company spanning pharmaceutical distribution, specialty logistics, pharmacy technology, and oncology services.

At its core, McKesson is a logistics and supply chain company operating at the intersection of pharmaceutical manufacturers and end-point care delivery. It buys drugs from ~1,500 manufacturers, warehouses them across ~32 distribution centers in the US, and delivers to ~40,000 pharmacy and healthcare provider locations — generating a spread between purchase and sale price, plus fees for ancillary services.

Mission: "Advancing Health Outcomes for All."

Business Segments (FY2024)

1. US Pharmaceutical (~85% of Revenue, ~65% of Adjusted Operating Profit)

The core distribution business. McKesson distributes branded and generic pharmaceuticals, specialty drugs, and over-the-counter products to:

• Retail national accounts: CVS, Rite Aid (primary distributor), other pharmacy chains
• Independent pharmacies: Community pharmacies (often enrolled in Health Mart franchise)
• Institutional: Hospitals, health systems, long-term care facilities
• Specialty providers: Oncology practices, specialty clinics, physician offices

Key economics: Branded drug distribution earns a fee-for-service spread (~1-2% of drug value, declining with drug price inflation on a dollar basis but growing on unit volume). Generic drugs earn wider spreads; ClarusONE JV (with WBA) consolidates generic purchasing to extract manufacturer discounts. GLP-1 drugs (Ozempic, Wegovy, Mounjaro) have become a rapidly growing distribution category.

Oncology Platform (within US Pharma but tracked separately):

• US Oncology Network: Largest community oncology network in the US with ~2,000 affiliated physicians across ~600 practices. Physicians remain independent but get group purchasing, billing, and operational support. Revenue recognized as drugs distributed to these practices.
• Ontada: Oncology data and technology platform; collects real-world evidence from US Oncology practices to support manufacturers and payers. Small revenue but strategic for margin enhancement.
• Specialty drug distribution (biosimilars, oncology, rare disease) is the highest-growth, highest-margin sub-segment within US Pharma.

2. Prescription Technology Solutions (RxTS) (~3-4% of Revenue, ~15% of Adjusted Operating Profit)

Technology and services that sit between pharmacy, payer, and manufacturer:

• CoverMyMeds: Electronic prior authorization platform; one of the largest in the US; processes ~19M+ prior authorization requests/year
• RelayHealth Pharmacy: Pharmacy connectivity network connecting pharmacies, payers, and PBMs
• AccessMed/RxCrossroads: Patient access programs, HUB services (reimbursement support for specialty drugs)
• Biologics Direct: Direct-to-patient specialty pharmacy fulfillment

RxTS earns technology fees from payers and manufacturers. Highest-margin segment; benefiting from complexity growth in specialty drug access.

3. Medical-Surgical Solutions (~6-7% of Revenue, ~10% of Adjusted Operating Profit)

Distributes medical-surgical supplies, lab products, and equipment to:

• Physician offices, surgery centers, long-term care, home care settings
• Built around acquisition of PSS World Medical and MedPartners

Primary customer: US government COVID-19 vaccine/test distribution program (now substantially wound down; created a large but temporary revenue/profit tailwind in FY2021–FY2023).

4. International (~4-5% of Revenue, diminishing)

McKesson has been exiting European pharmaceutical distribution operations:

• Divested German wholesale (Celesio/LLOYDS) operations
• Retaining Canadian operations (McKesson Canada) and limited European operations
• Segment is being wound down; management expects International contribution to become minimal by FY2026

Revenue by Customer Type (Approximate, FY2024)

Strategic Positioning

Core thesis: McKesson is migrating from commodity distributor to a healthcare infrastructure platform. The key transition is the growing weight of:

1. Specialty distribution (higher margin, higher barriers to entry)
2. US Oncology Network (recurring physician group relationships, data moat)
3. RxTS technology layer (software economics, recurring SaaS-like fees)

Management has guided to double-digit Adjusted EPS growth through FY2027 driven by:

• Specialty volume growth outpacing branded drug inflation
• GLP-1 drug tailwind (volume + distribution of new blockbusters)
• Share buybacks reducing share count ~7% annually
• RxTS and Oncology as mix-shift drivers toward higher margins

Competitive Position

McKesson commands ~33% of US pharmaceutical wholesale revenue, making it the largest of the "Big Three" distributors (MCK, COR/AmerisourceBergen, CAH/Cardinal Health). The market is an effective oligopoly — no new entrant has successfully entered at scale in 30+ years due to massive capital requirements, relationship lock-in, and thin margins that require scale to be profitable.

Recent Strategic Actions (FY2023–FY2025)

• Continued divestiture of European operations (RxTS Europe sold)
• Closed acquisition of Rx Savings Solutions (pharmacy cost transparency, employer benefits)
• Expanded US Oncology Network (added ~200 physicians FY2023–FY2024)
• Launched Ontada as formal brand for oncology data/analytics business
• Continued $3–4B+ annual share repurchase programs
• Settled national opioid litigation ($7.9B over 18 years, ~$440M/year)

source: coverage-next-full ticker: MCK step: "04" title: Financial Snapshot — 3-Year P&L Summary created: 2026-05-29

Step 04 — Financial Snapshot

3-Year Income Statement Summary

All figures in USD millions unless noted. McKesson fiscal year ends March 31.

Income Statement (GAAP)

Adjusted (Non-GAAP) P&L

McKesson's primary reporting metric is Adjusted Operating Profit and Adjusted EPS. These exclude: opioid litigation charges, amortization of acquisition-related intangibles, restructuring charges, and certain discrete tax items.

Note: GAAP EPS grew faster than Adjusted EPS in FY2022→FY2024 due to reversal of prior opioid charge accruals and lower prior-year GAAP base.

Profitability Analysis

Margin Structure

McKesson operates with razor-thin margins by design — it is a distribution business where scale, not margin, drives profitability. The key metrics are:

Key insight: Adjusted EPS growing at 16–17% CAGR despite revenue growing at ~14% reflects operating leverage + ~4–5% annual share count reduction via buybacks.

EPS Bridge (FY2023 → FY2024)

Cash Flow Summary

FCF quality: Highly consistent. FCF slightly exceeds Adjusted Net Income due to working capital benefits (McKesson collects from customers faster than it pays manufacturers in some programs). Capex is primarily IT/distribution infrastructure; moderate and predictable.

Balance Sheet Highlights (FY2024)

FY2025 and FY2026 Outlook (Consensus/Guidance)

McKesson guided FY2025 Adjusted EPS of $37.00–$37.80 (midpoint ~$37.40), implying ~19–21% growth from FY2024's $31.22.

Note: MCK typically guides conservatively and has a multi-year history of beating initial guidance.

Key Financial Ratios

Year-end prices approximate based on fiscal year-end (March 31) closing prices.

source: coverage-next-full ticker: MCK step: "12" title: Catalysts — Near-Term Drivers, Bull & Bear Cases created: 2026-05-29

Step 12 — Catalysts

Near-Term Catalysts (FY2025–FY2026)

Positive Catalysts

1. GLP-1 Volume Acceleration (6–12 month catalyst) GLP-1 agonist drugs (semaglutide, tirzepatide) are the fastest-growing pharmaceutical category. Novo Nordisk and Eli Lilly are significantly expanding manufacturing capacity in FY2025–FY2026. As supply increases, volume distributed through McKesson accelerates. Each $1B in additional GLP-1 drug sales generates ~$6–10M in distribution fees for McKesson (0.6–1.0% spread). Consensus expects GLP-1 drugs to reach $50B+ in US sales by 2027.

2. FY2025 Annual Earnings and Guidance Raise (Quarterly) McKesson has a consistent pattern of raising annual guidance 2–3x per year. FY2025 initial guidance of $32.40–$33.00 was raised to $37.00–$37.80 by Q3. The Q4 FY2025 earnings release (May 2025) + initial FY2026 guidance issuance is the largest annual catalyst. Consensus expects FY2026 Adjusted EPS of ~$43 — if McKesson guides above $42.50, stock typically re-rates higher.

3. US Oncology Network Expansion Milestones Each addition of physicians to US Oncology Network is a positive catalyst, particularly as specialty oncology drug volumes grow. New cancer drug approvals (especially high-cost biologics) that flow through US Oncology practices are incremental revenue.

4. Biosimilar Approvals & Distribution Wins The 2023–2025 wave of biosimilar approvals (particularly Humira biosimilars, adalimumab) creates new distribution opportunities. McKesson is well-positioned to distribute biosimilars through specialty channels. Each major biosimilar launch creates a 2–3 year distribution ramp.

5. European Operations Completion (Clarity Catalyst) As International segment divestitures complete, McKesson will be substantially a US-only business. This simplification should prompt multiple expansion as investors apply US Pharma/RxTS multiples to the consolidated entity rather than blending in lower-multiple international operations.

6. Rx Savings Solutions/Technology Integration Milestones Successful integration of Rx Savings Solutions (employer drug cost transparency) into McKesson's portfolio could open a new employer benefits market. Initial traction signals could be a positive catalyst.

Negative Catalysts to Watch

1. Rite Aid Liquidation (Known Risk) If Rite Aid stores accelerate closures, MCK faces volume headwind. Each 100-store closure is ~$1.5–2B in annual revenue impact. Current trajectory (500 stores closed, ~1,000 remaining) suggests ongoing quarterly headwinds.

2. GLP-1 Reimbursement Restrictions CMS restricts GLP-1 coverage for obesity (currently only covered for diabetes) → reduces pharmacy volume growth. This would be a near-term negative catalyst.

3. Initial FY2026 Guidance Below Consensus If MCK guides FY2026 initial Adjusted EPS below $42.00, market could reprice. Given guidance conservatism pattern, the risk is low but worth monitoring.

4. WBA Financial Distress / ClarusONE JV Risk Walgreens Boots Alliance has faced severe financial pressure (stock down 80%+ from peak; considering going private). If WBA collapses or is acquired, the ClarusONE JV could be restructured, potentially reducing McKesson's generic sourcing advantage.

Bull Case

• GLP-1 distribution volumes significantly exceed consensus as manufacturing capacity expands and Medicare obesity coverage extends, adding $500M+ annual profit by FY2027 while US Oncology Network reaches 3,000 physicians and drives oncology platform to 20%+ of total adjusted operating profit, justifying a re-rating to 23–24x forward EPS (from current ~20x) and pushing the stock to $750+
• Accelerated share buybacks at sub-$600 prices retire 8–9M shares per year vs. the 6M consensus assumption, adding an extra $2–3 in Adjusted EPS annually over the FY2025–FY2027 period
• Successful Rx Savings Solutions expansion into the employer benefit space opens a new $500M+ revenue stream, transforming RxTS into a $1.5B+ adjusted operating profit business by FY2027

Bear Case

• IRA drug price negotiation extends to specialty oncology drugs and GLP-1 agonists in the 2026–2028 negotiation cycle, reducing distributor economics by 15–20% on these high-growth categories and slowing adjusted EPS growth to mid-single digits vs. consensus mid-teens
• Walgreens Boots Alliance financial distress leads to ClarusONE JV dissolution or renegotiation, costing McKesson $150–250M in annual cost advantage and pressuring gross margins by 10–20bps
• Amazon Pharmacy expands into wholesale distribution by acquiring a regional distributor or building out DEA infrastructure, capturing 5–8% market share by 2028 and forcing MCK to cut fees to retain key pharmacy chain customers